Christopher Yea Biography and Net Worth

Chris holds a BSc and PhD in Biochemistry from the University of Bristol, UK. Following post-doctoral work, he spent several years at Roussel-UCLAF and Hoechst Marion Roussel before joining Ferring Pharmaceuticals. Chris led the Biology group and was responsible for transition of candidates into development. In 2008, Chris co-led the spin-out of Vantia Ltd and most recently was Chief Operating Officer where he was responsible for development activities through Phase 3 trials.

In his position as Chief Development Officer, Chris is responsible for all development-related activities within KalVista Pharmaceuticals.

What is Christopher Yea's net worth?: The estimated net worth of Christopher Yea is at least $1.01 million as of August 19th, 2024. Dr. Yea owns 84,467 shares of KalVista Pharmaceuticals stock worth more than $1,007,691 as of March 30th. This net worth estimate does not reflect any other investments that Dr. Yea may own. Additionally, Dr. Yea receives an annual salary of $708,530.00 as Insider at KalVista Pharmaceuticals. Learn More about Christopher Yea's net worth.
How old is Christopher Yea?: Dr. Yea is currently 60 years old. There are 6 older executives and no younger executives at KalVista Pharmaceuticals. Learn More on Christopher Yea's age.
What is Christopher Yea's salary?: As the Insider of KalVista Pharmaceuticals, Inc., Dr. Yea earns $708,530.00 per year. There are 2 executives that earn more than Dr. Yea. The highest earning executive at KalVista Pharmaceuticals is Mr. Benjamin L. Palleiko, CEO & Director, who commands a salary of $983,070.00 per year. Learn More on Christopher Yea's salary.
How do I contact Christopher Yea?: The corporate mailing address for Dr. Yea and other KalVista Pharmaceuticals executives is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. KalVista Pharmaceuticals can also be reached via phone at 857-999-0075 and via email at ir@kalvista.com. Learn More on Christopher Yea's contact information.
Has Christopher Yea been buying or selling shares of KalVista Pharmaceuticals?: Christopher Yea has not been actively trading shares of KalVista Pharmaceuticals in the last ninety days. Most recently, Christopher Yea sold 7,102 shares of the business's stock in a transaction on Monday, August 19th. The shares were sold at an average price of $12.01, for a transaction totalling $85,295.02. Following the completion of the sale, the insider now directly owns 84,467 shares of the company's stock, valued at $1,014,448.67. Learn More on Christopher Yea's trading history.
Who are KalVista Pharmaceuticals' active insiders?: KalVista Pharmaceuticals' insider roster includes Thomas Crockett (CEO), Edward Feener (Insider), Andreas Maetzel (SVP), Michael Smith (VP), and Christopher Yea (Insider). Learn More on KalVista Pharmaceuticals' active insiders.
Are insiders buying or selling shares of KalVista Pharmaceuticals?: During the last year, KalVista Pharmaceuticals insiders bought shares 5 times. They purchased a total of 236,055 shares worth more than $2,162,146.35. During the last year, insiders at the specialty pharmaceutical company sold shares 15 times. They sold a total of 117,899 shares worth more than $1,300,246.77. The most recent insider tranaction occured on March, 7th when CEO Benjamin L Palleiko sold 6,669 shares worth more than $79,827.93. Insiders at KalVista Pharmaceuticals own 10.5% of the company. Learn More about insider trades at KalVista Pharmaceuticals.
Information on this page was last updated on 3/7/2025.

Christopher Yea Insider Trading History at KalVista Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/19/2024	Sell	7,102	$12.01	$85,295.02	84,467
5/18/2023	Sell	2,604	$10.14	$26,404.56	37,310
11/18/2022	Sell	1,139	$5.44	$6,196.16	34,232
8/2/2021	Sell	5,000	$20.52	$102,600.00	8,234
5/3/2021	Sell	5,000	$24.84	$124,200.00	42,969
2/23/2021	Sell	15,000	$33.59	$503,850.00	62,169
10/29/2020	Sell	5,000	$17.48	$87,400.00	62,969
10/20/2020	Sell	7,942	$17.49	$138,905.58	76,315
10/16/2020	Sell	914	$17.00	$15,538.00	81,955
12/16/2019	Sell	3,010	$17.05	$51,320.50	83,168
12/13/2019	Sell	1,500	$17.05	$25,575.00	83,168
4/22/2019	Sell	7,355	$26.04	$191,524.20	90,324
1/25/2019	Sell	5,453	$17.06	$93,028.18	88,422
1/23/2019	Sell	1,902	$17.01	$32,353.02	84,271

Christopher Yea Buying and Selling Activity at KalVista Pharmaceuticals

KalVista Pharmaceuticals Company Overview

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $11.93

$11.82

$12.50

50 Day Range

MA: $10.56

$8.30

$12.60

2 Week Range

Now: $11.93

$7.30

$15.50

Volume

275,700 shs

Average Volume

386,462 shs

Market Capitalization

$593.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Christopher Yea Biography and Net Worth

What is Christopher Yea's net worth?

How old is Christopher Yea?

What is Christopher Yea's salary?

How do I contact Christopher Yea?

Has Christopher Yea been buying or selling shares of KalVista Pharmaceuticals?

Who are KalVista Pharmaceuticals' active insiders?

Are insiders buying or selling shares of KalVista Pharmaceuticals?